Spiegelberg J, Neeff H, Holzner P, Runkel M, Fichtner-Feigl S, Glatz T. Comparison of hyperthermic intraperitoneal chemotherapy regimens for treatment of peritoneal-metastasized colorectal cancer. World J Gastrointest Oncol 2020; 12(8): 903-917 [PMID: 32879667 DOI: 10.4251/wjgo.v12.i8.903]
Corresponding Author of This Article
Torben Glatz, MD, Surgeon, Department of Surgery, Marien Hospital Herne, Ruhr-University Bochum, Hölkeskampring 40, Herne 44625, Germany. torben.glatz@uniklinik-freiburg.de
Research Domain of This Article
Surgery
Article-Type of This Article
Retrospective Cohort Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Oncol. Aug 15, 2020; 12(8): 903-917 Published online Aug 15, 2020. doi: 10.4251/wjgo.v12.i8.903
Comparison of hyperthermic intraperitoneal chemotherapy regimens for treatment of peritoneal-metastasized colorectal cancer
Julia Spiegelberg, Hannes Neeff, Philipp Holzner, Mira Runkel, Stefan Fichtner-Feigl, Torben Glatz
Julia Spiegelberg, Hannes Neeff, Philipp Holzner, Mira Runkel, Stefan Fichtner-Feigl, Torben Glatz, Department of General and Visceral Surgery, Medical Center – University of Freiburg, Freiburg 79106, Germany
Torben Glatz, Department of Surgery, Marien Hospital Herne, Ruhr-University Bochum, Herne 44625, Germany
Author contributions: All authors solely contributed to the preparation of this manuscript.
Institutional review board statement: The study was approved by the Medical Ethics Committee of the University of Freiburg (EK-FR 4/20).
Informed consent statement: All study participants or their legal guardian provided informed written consent about personal and medical data collection prior to study enrolment.
Conflict-of-interest statement: All the authors have no conflict of interest related to the manuscript.
Data sharing statement: The original anonymous dataset is available on request from the corresponding author at torben.glatz@uniklinik-freiburg.de.
STROBE statement: The guidelines of the STROBE Statement have been adopted.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Torben Glatz, MD, Surgeon, Department of Surgery, Marien Hospital Herne, Ruhr-University Bochum, Hölkeskampring 40, Herne 44625, Germany. torben.glatz@uniklinik-freiburg.de
Received: December 30, 2019 Peer-review started: December 30, 2019 First decision: February 20, 2020 Revised: May 29, 2020 Accepted: June 14, 2020 Article in press: June 14, 2020 Published online: August 15, 2020
Core Tip
Core tip: We evaluated the therapeutic efficiency of cytoreductive surgery in combination with two different hyperthermic intraperitoneal chemotherapy (HIPEC) regimens, comparing mitomycin C HIPEC vs oxaliplatin HIPEC. We therefore retrospectively evaluated 102 patients undergoing cytoreductive surgery and HIPEC and statistically analysed demographics, perioperative complication and survival outcome. We found no difference in median overall survival between mitomycin C and oxaliplatin HIPEC. Regarding postoperative complications, patients treated with oxaliplatin HIPEC suffered an increased complication rate. Regarding multivariate analysis of survival, primary distant metastasis and primary tumour resection seem to have a significant impact on survival and likewise peritoneal cancer index-scoring regarding peritoneal carcinomatosis. Further prospective studies comparing HIPEC regimens would improve therapeutic decision-making.
